1-cyclopentyl-N-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-5-oxo-3-pyrrolidinecarboxamide is a complex organic molecule with a long and descriptive chemical name.
**It's important to understand that without further context, it's impossible to say definitively why this specific compound is important for research. ** It could be:
* **A potential drug candidate:** This compound might be a lead compound in drug discovery, exhibiting potential therapeutic effects for a specific disease.
* **A tool compound:** It could be used as a probe to study the activity of specific biological targets, such as enzymes or receptors.
* **A synthetic intermediate:** It could be a key building block in the synthesis of other more complex molecules.
* **A model compound:** It might be used to study the structure-activity relationships of a larger class of compounds.
**To understand the specific importance of this compound, you would need more information, including:**
* **The context of the research:** What is the area of research? What is the goal?
* **The properties of the compound:** Does it have specific biological activities? What is its chemical structure?
**To find this information, you could:**
* **Search scientific databases:** Look for publications or patents mentioning this compound.
* **Contact the researchers who synthesized or studied it:** If you know who they are, you could reach out to them directly.
**Please note:** I'm an AI, and I cannot provide medical or scientific advice.
| ID Source | ID |
|---|---|
| PubMed CID | 3241136 |
| CHEMBL ID | 1412019 |
| CHEBI ID | 109370 |
| Synonym |
|---|
| smr000032319 |
| MLS000096370 , |
| 1-cyclopentyl-n-[2-(3,4-dihydroisoquinolin-2(1h)-yl)ethyl]-5-oxopyrrolidine-3-carboxamide |
| CHEMDIV2_008213 |
| EU-0064526 |
| CHEBI:109370 |
| HMS1392F07 |
| 1-cyclopentyl-n-[2-(3,4-dihydro-1h-isoquinolin-2-yl)ethyl]-5-oxopyrrolidine-3-carboxamide |
| HMS2477N10 |
| AKOS024602305 |
| 1-cyclopentyl-n-(2-(3,4-dihydroisoquinolin-2(1h)-yl)ethyl)-5-oxopyrrolidine-3-carboxamide |
| 850781-08-7 |
| F0920-7392 |
| 1-cyclopentyl-n-[2-(3,4-dihydro-1h-isoquinolin-2-yl)ethyl]-5-oxidanylidene-pyrrolidine-3-carboxamide |
| 1-cyclopentyl-n-[2-(3,4-dihydro-1h-isoquinolin-2-yl)ethyl]-5-keto-pyrrolidine-3-carboxamide |
| bdbm45374 |
| cid_3241136 |
| 1-cyclopentyl-n-[2-(3,4-dihydro-1h-isoquinolin-2-yl)ethyl]-5-oxo-3-pyrrolidinecarboxamide |
| CHEMBL1412019 |
| Q27188486 |
| VU0116414-5 |
| sr-01000161286 |
| SR-01000161286-1 |
| Class | Description |
|---|---|
| isoquinolines | A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 89.1251 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 35.4813 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 5.0119 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 10.0000 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.0018 | 15.6638 | 39.8107 | AID894 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 0.8913 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 79.4328 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| geminin | Homo sapiens (human) | Potency | 0.2593 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 0.8913 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Coagulation factor XII | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0104 | 3.8890 | 10.9666 | AID852 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| serine-type endopeptidase activity | Coagulation factor XII | Homo sapiens (human) |
| calcium ion binding | Coagulation factor XII | Homo sapiens (human) |
| protein binding | Coagulation factor XII | Homo sapiens (human) |
| misfolded protein binding | Coagulation factor XII | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Coagulation factor XII | Homo sapiens (human) |
| extracellular space | Coagulation factor XII | Homo sapiens (human) |
| plasma membrane | Coagulation factor XII | Homo sapiens (human) |
| collagen-containing extracellular matrix | Coagulation factor XII | Homo sapiens (human) |
| extracellular exosome | Coagulation factor XII | Homo sapiens (human) |
| extracellular space | Coagulation factor XII | Homo sapiens (human) |
| rough endoplasmic reticulum | Coagulation factor XII | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||